Longeveron to Present at Biotech Showcase 2025
Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its upcoming participation at Biotech Showcase 2025. CEO Wa'el Hashad will deliver a corporate presentation on Tuesday, January 14, 2025, from 4:00 to 4:30 p.m. PT.
The company, which focuses on developing cellular therapies for life-threatening and chronic aging-related conditions, will make the presentation available via webcast through the 'Events and Presentations' section of their website. A replay will be accessible on Longeveron's website after the conference concludes.
Longeveron (NASDAQ: LGVN), un'azienda biotecnologica in fase clinica specializzata nella medicina rigenerativa, ha annunciato la sua partecipazione al Biotech Showcase 2025. Il CEO Wa'el Hashad presenterà una relazione aziendale martedì 14 gennaio 2025, dalle 16:00 alle 16:30 PT.
L'azienda, che si concentra sullo sviluppo di terapie cellulari per condizioni croniche e legate all'invecchiamento che mettono in pericolo la vita, renderà disponibile la presentazione tramite webcast nella sezione 'Eventi e Presentazioni' del loro sito web. Una registrazione sarà accessibile sul sito di Longeveron dopo la conclusione della conferenza.
Longeveron (NASDAQ: LGVN), una empresa biotecnológica en etapa clínica especializada en medicina regenerativa, ha anunciado su próxima participación en el Biotech Showcase 2025. El CEO Wa'el Hashad ofrecerá una presentación corporativa el martes 14 de enero de 2025, de 4:00 a 4:30 p.m. PT.
La empresa, que se centra en el desarrollo de terapias celulares para afecciones crónicas y relacionadas con el envejecimiento que son potencialmente mortales, pondrá la presentación a disposición a través de un webcast en la sección 'Eventos y Presentaciones' de su sitio web. Una grabación estará disponible en el sitio web de Longeveron después de que concluyan las conferencias.
Longeveron (NASDAQ: LGVN), 임상 단계 재생 의학 생명공학 회사가 Biotech Showcase 2025에 참여할 예정이라고 발표했습니다. CEO Wa'el Hashad는 2025년 1월 14일 화요일 오후 4시부터 4시 30분(PT)까지 기업 발표를 진행할 예정입니다.
생명과 관련된 만성 노화 질환 치료법 개발에 중점을 두고 있는 이 회사는 '이벤트 및 발표' 섹션을 통해 발표를 웹캐스트로 제공할 예정입니다. 컨퍼런스가 종료된 후 Longeveron 웹사이트에서 재생을 제공할 것입니다.
Longeveron (NASDAQ: LGVN), une entreprise biotechnologique en phase clinique spécialisée dans la médecine régénérative, a annoncé sa prochaine participation au Biotech Showcase 2025. Le PDG Wa'el Hashad fera une présentation d'entreprise le mardi 14 janvier 2025, de 16h00 à 16h30 PT.
L'entreprise, qui se concentre sur le développement de thérapies cellulaires pour des conditions mettant la vie en danger et liées au vieillissement, mettra la présentation à disposition via un webcast dans la section 'Événements et Présentations' de son site Web. Une rediffusion sera accessible sur le site de Longeveron après la fin de la conférence.
Longeveron (NASDAQ: LGVN), ein biopharmazeutisches Unternehmen in der klinischen Phase für regenerative Medizin, hat seine bevorstehende Teilnahme am Biotech Showcase 2025 angekündigt. CEO Wa'el Hashad wird am Dienstag, den 14. Januar 2025, von 16:00 bis 16:30 Uhr PT einen Unternehmensvortrag halten.
Das Unternehmen, das sich auf die Entwicklung von Zelltherapien für lebensbedrohliche und chronische altersbedingte Erkrankungen konzentriert, wird die Präsentation über einen Webcast im Bereich 'Veranstaltungen und Präsentationen' auf seiner Website zur Verfügung stellen. Eine Aufzeichnung wird nach Abschluss der Konferenz auf der Website von Longeveron zugänglich sein.
- None.
- None.
MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, Chief Executive Officer, will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Details for the Company’s presentation:
| Date: | Tuesday, January 14, 2025 |
| Time: | 4:00 – 4:30 p.m. PT |
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Aging-related Frailty. Lomecel-B™ development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
When is Longeveron (LGVN) presenting at Biotech Showcase 2025?
How can investors watch Longeveron's (LGVN) Biotech Showcase 2025 presentation?
What type of therapies is Longeveron (LGVN) developing?
Who will be presenting for Longeveron (LGVN) at Biotech Showcase 2025?
